Clinical Trials
6 trialsNCT03822117 2025-11-04
Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)
Incyte Corporation
Phase 2 Terminated
NCT04003610 2025-11-04
Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)
Incyte Corporation
Phase 2 Terminated
NCT03144661 2025-10-21
An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies
Incyte Corporation
Phase 1 Terminated
NCT04604132 2024-04-04
FIDES-03
Basilea Pharmaceutica
Phase 1/2 Terminated
NCT03762122 2022-11-09
Rogaratinib in Patients With Advanced Pretreated Squamous-cell Non-small Cell Lung Cancer (SQCLC)
Swiss Cancer Institute
Phase 2 Terminated
NCT01367275 2020-09-03
Irinotecan Plus Brivanib in Metastatic Colorectal Cancer (CRC) Enriched for Elevated Levels of Plasma FGF
M.D. Anderson Cancer Center
Phase 2 Terminated